KRAS
Other names: KRAS G12C, KRAS G12D, KRAS mutation
Some specific KRAS changes in lung cancer can now be targeted, while others remain limited to standard pathways or clinical trials.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
KRAS is a gene that regulates growth signals. Mutations in this gene are quite common findings in lung cancer. What matters is the specific type of change, not just the mutation status.
Clinical meaning
KRAS G12C alterations have specific inhibitor options, while other alterations are generally directed to standard pathways or clinical trials. KRAS mutations often appear together with other markers such as STK11 or KEAP1, which can also influence the discussion.
Testing methods
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
- KRAS PCR
A focused test for specific changes in the KRAS gene.
- Liquid biopsy (ctDNA)
A blood test that looks for tumour genetic material to supplement or partly replace tissue testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Specific codon and amino acid changes in laboratory reports.
- Does the molecular panel also report co-mutation markers?
- PD-L1 status, because it is sometimes discussed together.
- Availability of medicines in Indonesia and financing channels.
Related drugs
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT07020221Phase 1 / Phase 2Combination regimen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Lung Cancer | biomarker: KRAS | Immunotherapy, Targeted therapy, Chemotherapy
United States, Australia15 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07020221Not verified
NCT07458347Phase 1Immunotherapy
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Lung Cancer | biomarker: KRAS | Immunotherapy, Chemotherapy
United States9 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07458347Not verified
NCT07468071Phase 1 / Phase 2Targeted therapy
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Lung Cancer | biomarker: KRAS | Targeted therapy
Belgium, Canada, China +720 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Active, not recruiting
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07468071Not verified
NCT07659782Phase 2Targeted therapy
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Lung Cancer | biomarker: KRAS | Targeted therapy
United States, Australia, Puerto Rico22 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07659782Not verified
NCT07594067Phase 1Combination regimen
TCR1188-ABC Cells in KRAS-mutated Cancers
Lung Cancer | biomarker: KRAS | Stem cell transplant, Chemotherapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Stem cell transplant.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07594067Not verified
NCT05786924Phase 1 / Phase 2Targeted therapy
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Lung Cancer | biomarker: KRAS, BRAF | Targeted therapy, Chemotherapy
United States, Australia, China +749 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05786924Not verified
Check options based on your result
Share the KRAS result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Colorectal Cancer
Cancer type
Reason: Related through a biomarker
- Pancreatic Cancer
Cancer type
Reason: Related through a biomarker
- Newly diagnosed lung cancer
Decision situation
Reason: Related through a biomarker
- Metastatic lung cancer
Decision situation
Reason: Related through a biomarker
- KRAS G12C
Molecular alteration
Reason: Related through a biomarker
- KRAS G12D
Molecular alteration
Reason: Related through a biomarker
To check
- Liquid biopsy (ctDNA)
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- KRAS PCR
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.